Pancreatic ductal adenocarcinoma (PDAC) is the most common pancreatic malignancy and is characterized by aggressive behavior and a poor prognosis, with a 5-year overall survival rate of < 10% [1,2]. Large-duct PDAC (LD-PDAC) is a recently recognized morphologic variant of PDAC and is characterized by dilated glandular structures (i.e., large cancer glands) that comprise more than 50% of the tumor [3–5].